Singapore Property Review

It will be the firm’s biggest single manufacturing investment

By CHEN HUIFEN

(SINGAPORE) Swiss drug giant Novartis Pharma will invest another US$700 million in Singapore - hot on the heels of a US$180 million plant it opened yesterday.

 The US$700 million is for a major plant to produce protein-based drugs, known also as biologics or biopharmaceuticals.

It will be close to the company’s existing plant that makes drugs from chemically-synthesised substances.

‘We have six facilities at the moment in biopharmaceutical operations - five in Europe and one in California,’ said Novartis head of global biopharmaceutical operations Thibaud Stoll. ‘This new one will expand our operations in Asia and also in biopharmaceuticals.’

Full Article at BT…

 See Mr Lim’s full speech…

This entry was posted on Tuesday, October 30th, 2007 at 8:28 am and is filed under Newspaper Clipping. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.